Adenoidectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Adenoidectomy is the surgical removal of the adenoids — a mass of lymphoid tissue located in the posterior nasopharynx at the back of the nasal cavity, forming part of Waldeyer's tonsillar ring along with the palatine tonsils, lingual tonsil, and tubal tonsils. Adenoids are present in children from birth, reach maximum size between ages 3-7, and typically regress naturally through adolescence. Their physiological role involves immune surveillance and IgA production for mucosal immunity during early childhood.

Adenoid hypertrophy — abnormal enlargement relative to the nasopharyngeal airway space — causes characteristic symptoms including nasal obstruction (mouth breathing, snoring, nasal voice quality), obstructive sleep apnea syndrome (OSAS), recurrent or chronic otitis media with effusion (glue ear) due to Eustachian tube obstruction, recurrent sinusitis from impaired mucociliary clearance, and the characteristic 'adenoid facies' of chronic mouth breathing (open mouth posture, long narrow face, dental crowding). Adenoidectomy effectively addresses these symptoms by restoring nasopharyngeal airway patency.

Adenoidectomy is one of the most commonly performed surgical procedures in children globally, with approximately 130,000 procedures performed annually in the United States and 30,000 in the United Kingdom. It is performed under general anaesthesia as a day-case procedure typically lasting 15-30 minutes, using transoral access without any external incision. It is very frequently combined with tonsillectomy (adenotonsillectomy) for children with both tonsillar and adenoid enlargement contributing to obstructive symptoms, and with bilateral myringotomy and grommet insertion for persistent otitis media with effusion.

The procedure is generally performed in children aged 2-12, although adult adenoid hypertrophy (less common, may relate to nasopharyngeal lymphoid hyperplasia in HIV or EBV infection) does occur and is similarly managed.

Adenoidectomy is indicated for several distinct clinical presentations of adenoid hypertrophy. Obstructive sleep apnea syndrome (OSAS) in children — characterised by snoring, observed apnoeas, restless sleep, night sweats, and daytime behavioural consequences including hyperactivity, reduced school performance, and bedwetting — is the most compelling indication, as paediatric OSAS carries risks of growth impairment, neurocognitive development delay, and cardiovascular effects from chronic nocturnal hypoxaemia. Adenotonsillectomy is the primary treatment for OSAS in children aged 3-12 with tonsillar and adenoid hypertrophy.

Recurrent or chronic otitis media with effusion (OME, 'glue ear') causing conductive hearing loss is the second major indication. Eustachian tube dysfunction from adenoid hypertrophy impairs middle ear ventilation, leading to persistent fluid in the middle ear space and a 20-30 dB conductive hearing loss affecting speech development. In children with recurrent OME not responding to 3 months of watchful waiting or hearing aid use, adenoidectomy (often combined with grommet insertion) reduces OME recurrence. Recurrent acute otitis media (AOM) — 4 or more episodes per year — is reduced in frequency by adenoidectomy, particularly in children over 4 years. Severe adenoid hypertrophy causing significant nasal obstruction with mouth breathing, recurrent adenoid infection, and adenoid-related chronic sinusitis are further indications.

Adenoidectomy is recommended for children with documented significant adenoid hypertrophy (typically Grade 3-4 on nasopharyngoscopy, with 75-90% of nasopharyngeal airway obstructed) causing symptomatic obstructive sleep apnea, chronic or recurrent otitis media with hearing loss, or significant nasal obstructive symptoms affecting quality of life and school performance. A polysomnography (overnight sleep study) is recommended before adenotonsillectomy for OSAS to document severity and guide prioritisation, particularly in children at higher risk — obesity, Down syndrome, cerebral palsy, or craniofacial abnormalities.

Contraindications include active upper respiratory tract infection (surgery should be deferred 4 weeks after acute infection resolves), submucous cleft palate (which may be unmasked or worsened by adenoidectomy with resultant velopharyngeal insufficiency and hypernasal speech — always palpate the soft palate before adenoidectomy), severe coagulopathy requiring pre-operative haematological optimisation, and very young children under 2 years (where immune consequences of lymphoid tissue removal are more significant, though the procedure can be performed when clinical necessity is compelling). Sickle cell disease requires pre-operative haematological optimisation with exchange transfusion or hydroxyurea therapy.

Conventional curettage adenoidectomy uses a mirror-guided curette to blindly scrape the adenoid pad from the roof and posterior wall of the nasopharynx. It is fast (5-10 minutes), inexpensive, and widely performed in resource-limited settings, but its blind nature limits completeness of removal and increases residual and recurrent adenoid tissue rates. Adenoid re-growth requiring re-operation occurs in 10-20% of cases with curette technique.

Endoscopic adenoidectomy uses a 30-degree or 70-degree rigid nasal endoscope to visualise the adenoid pad directly under magnified view, combined with powered microdebrider or radiofrequency coblation for tissue removal. This technique achieves complete adenoid removal under direct vision, significantly reduces the risk of residual tissue and need for re-operation, and is rapidly becoming the preferred approach at specialist ENT centres. Coblation adenoidectomy uses low-temperature radiofrequency energy to ablate adenoid tissue with minimal thermal damage to surrounding structures, reducing immediate post-operative bleeding risk and allowing faster recovery. Combined adenotonsillectomy addresses both adenoid and palatine tonsil hypertrophy in a single procedure. Adenoidectomy combined with myringotomy and grommet insertion performs adenoid removal alongside ventilation tube placement for concurrent OME, offering combined treatment of two connected conditions in one anaesthetic episode.

Selecting the most appropriate Adenoidectomy approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Adenotonsillectomy for paediatric OSAS achieves resolution of obstructive sleep apnea in 70-80% of healthy-weight children, with improvement in sleep architecture, reduction in apnoea-hypopnoea index (AHI) to less than 5 events per hour in most cases, and significant improvements in quality of life, daytime behaviour, and school performance. The CHAT (Childhood Adenotonsillectomy Trial) published in NEJM (2013) demonstrated that adenotonsillectomy significantly improved behaviour, quality of life, and polysomnographic parameters compared to watchful waiting, though neurocognitive primary outcomes were not statistically significant in this study — a finding that does not contradict the substantial clinical improvement observed.

For otitis media with effusion, adenoidectomy combined with grommets reduces OME recurrence by 30-40% over grommets alone in children over 4 years, improving hearing and reducing the need for repeat grommet insertion. Nasal obstructive symptoms — mouth breathing, snoring, nasal voice — resolve in 80-90% of children with adenoid hypertrophy as the primary cause. Overall parent-reported quality-of-life improvement at 1 year is consistently high (above 85%) in surgical compared to watchful waiting groups across multiple RCTs.

Post-operative bleeding (primary haemorrhage within 24 hours or secondary haemorrhage at 5-10 days) is the most significant complication, occurring in 1-3% of adenoidectomy cases. Secondary haemorrhage — typically from separation of the wound slough at day 5-8 — may require return to theatre for haemostasis under anaesthesia. Primary haemorrhage in the recovery room is managed immediately and rarely requires transfusion. All families are instructed to bring children back to the emergency department immediately if bleeding occurs after discharge.

Velopharyngeal insufficiency (VPI) — the inability of the soft palate to close completely against the pharyngeal walls, causing hypernasal speech — is a rare but significant complication (0.1-0.3%) particularly in children with undetected submucous cleft palate. VPI usually improves over 3-6 months as the nasopharyngeal musculature adapts; persistent VPI may require speech therapy or surgical repair. Nasopharyngeal stenosis — scarring and cicatricial narrowing of the nasopharynx — is an extremely rare complication (less than 0.1%) associated with over-aggressive adenoid removal extending onto the lateral nasopharyngeal walls. Respiratory complications in the post-anaesthesia care unit include hypoxaemia in children with severe pre-operative OSAS, who require careful post-operative monitoring and may benefit from overnight hospital observation rather than day-case discharge.

Adenoidectomy recovery for children is generally rapid. Most children are discharged 2-4 hours after the procedure once they are awake, comfortable, tolerating oral fluids, and have not shown any bleeding. A soft diet for 7-10 days reduces mechanical irritation of the healing nasopharynx. Regular liquid paracetamol (acetaminophen) and ibuprofen provide effective analgesia; NSAIDs are safe in children and do not increase bleeding risk at standard doses. Children typically return to normal activities within 5-7 days and to school within 1-2 weeks.

Post-operative ENT review is scheduled at 4-6 weeks to assess wound healing, confirm symptom resolution, and perform audiometric testing if the procedure included grommet insertion. For children who had OSAS as the indication, a repeat polysomnography at 6-8 weeks confirms adequacy of surgical cure, particularly important in overweight children, those with craniofacial syndromes, or those with residual symptoms. The risk of adenoid re-growth is approximately 10-20% with curette technique and 5% with endoscopic technique, presenting within 1-3 years of surgery; recurrent symptoms require nasopharyngoscopy to confirm regrowth before re-operation.

Adenoidectomy in the United States costs $5,000-$10,000 as a private procedure including anaesthesia and surgical facility fees. Combined adenotonsillectomy costs $8,000-$15,000. In the United Kingdom, adenoidectomy is NHS-funded for appropriate paediatric indications; private ENT surgery costs £2,000-£5,000. In Australia, the procedure is covered under Medicare for public patients with waiting lists of several months.

At paediatric ENT surgery centres in India — Apollo Hospitals, Fortis Healthcare, Manipal Hospitals — adenoidectomy costs $800-$1,500 for the complete surgical episode, and combined adenotonsillectomy costs $1,200-$2,500. Thailand (Samitivej Children's Hospital, Bangkok Hospital) charges $1,000-$2,500. The quality and safety of paediatric anaesthesia at JCI-accredited Indian and Thai hospitals is fully equivalent to Western standards. For families considering medical tourism for paediatric ENT surgery, India and Thailand offer the most compelling cost-quality combination, with many hospitals having dedicated paediatric wards and child life specialists.

Watchful waiting with active monitoring is appropriate for children with mild-to-moderate adenoid hypertrophy and mild OME who have no significant hearing loss (less than 25 dB), as 50-60% of OME episodes resolve spontaneously within 3 months. NICE guideline CKS for OME recommends watchful waiting for 3 months in children over 3 years with confirmed OME before surgical referral. For mild obstructive symptoms without OSAS, watchful waiting with parental education about obesity management and nasal hygiene is reasonable.

Intranasal corticosteroid nasal sprays (fluticasone, mometasone) have evidence from meta-analyses for modestly reducing adenoid hypertrophy and OME in the short term, and are an appropriate first-line trial for children with mild symptoms before surgical referral. The therapeutic benefit is typically modest and temporary, with adenoid regrowth when steroids are discontinued. Continuous positive airway pressure (CPAP) is an alternative for managing obstructive sleep apnea in children who are not surgical candidates, though adherence in young children is challenging and it is not a permanent solution. For recurrent otitis media, pneumococcal vaccination (PCV13) and influenza vaccination reduce the frequency of otitis media episodes and are recommended as preventive measures alongside surgical consideration.